Oncosil Medical (OSL.AX) Stock Price
Oncosil Medical Price
Revenue at Oncosil Medical has contracted by 1.0% per year over the past 19 years to 1.26 M AUD. For Oncosil Medical, the net margin of -1,196.8% is down versus -755.6% a few years ago. The stock trades about 118% above its 52-week low.
Oncosil Medical stock price
Oncosil Medical business model & stock analysis
Frequently asked questions about Oncosil Medical
The business model of Oncosil Medical Ltd focuses on developing and commercializing innovative medical devices for the treatment of various cancers. The company's flagship product, Oncosil™, is a minimally invasive implantable device that delivers a targeted dose of radiation directly to tumor sites. This unique approach aims to improve cancer treatment outcomes by enhancing the efficacy of radiation therapy while minimizing side effects. Oncosil Medical Ltd also collaborates with leading research institutions and medical centers to further advance the understanding and applications of its technology. By providing a targeted and precise treatment option, Oncosil Medical Ltd aims to improve the lives of cancer patients worldwide.
Oncosil Medical Ltd is primarily active in the healthcare industry.
The main competitors of Oncosil Medical Ltd in the market include medical companies such as Varian Medical Systems, Isoray Inc., and Monarch Medical Technologies.
Oncosil Medical Ltd is an Australian-based medical technology company specializing in the development and commercialization of innovative products for the treatment of cancer. Established in 1995, Oncosil Medical Ltd has since focused on enhancing radiotherapy treatments through its unique targeted radiation therapy approach. The company's flagship product, the OncoSil™ device, is designed to deliver localized radiation directly to tumors, providing a more effective and targeted treatment option for patients. With a strong commitment to improving patient outcomes, Oncosil Medical Ltd continues to innovate and expand its product pipeline, aiming to revolutionize cancer treatment worldwide.
Oncosil Medical Ltd has achieved several significant milestones. Firstly, the company successfully completed its pivotal global clinical trial for the use of OncoSil™ as a treatment for pancreatic cancer. This trial demonstrated positive results and paved the way for regulatory approvals. Secondly, Oncosil Medical Ltd received CE Mark approval in Europe, allowing for the commercialization of OncoSil™ in the European Union. Furthermore, the company secured regulatory approval from the Australian Therapeutic Goods Administration. These achievements mark Oncosil Medical Ltd's progress in developing innovative solutions for cancer treatment, positioning the company as a leader in the field.
Oncosil Medical Ltd is primarily present in Australia.
Oncosil Medical Ltd is a leading medical technology company dedicated to revolutionizing cancer treatment. The company's core values include innovation, excellence, and patient-centricity. Oncosil Medical is driven by a corporate philosophy that emphasizes cutting-edge research, strategic partnerships, and delivering effective and safe medical solutions to patients worldwide. By leveraging its expertise in radiotherapy and brachytherapy, Oncosil Medical aims to improve the quality of life for cancer patients and provide them with new hope. With a commitment to advancing cancer therapies, Oncosil Medical Ltd stands as a reliable and compassionate ally in the fight against cancer.
7 analysts currently rate the Oncosil Medical stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect Oncosil Medical to generate revenue of 2.20 M AUD and earnings per share of -0.00 AUD.
Converted at the current exchange rate, the Oncosil Medical share trades at 0.52 EUR (0.85 AUD).
The Oncosil Medical share (OSL.AX) is listed on 1 stock exchanges, including: ASX (OSL.AX).
Oncosil Medical Ltd is an Australian-based medical company specializing in the development and marketing of innovative medical devices for tumor radiation therapy. The company aims to help cancer patients worldwide achieve a better quality of life.
The expected revenue of Oncosil Medical is 2.20 M AUD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Oncosil Medical is -10,928.30 AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Oncosil Medical is currently -850.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Oncosil Medical stock.
The price-to-sales ratio (P/S) of Oncosil Medical is currently 4.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Oncosil Medical stock.
The Eulerpool Quality Score for Oncosil Medical is 3/10.
The ISIN of Oncosil Medical is AU000000OSL3. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Oncosil Medical is A1WZU4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Oncosil Medical is OSL.AX. The ticker symbol is used to trade Oncosil Medical shares on the stock exchange.
Oncosil Medical paid dividends every year for the past 0 years.
Oncosil Medical is assigned to the 'Health' sector.
The dividends of Oncosil Medical are distributed in AUD.
Oncosil Medical stock
Oncosil Medical Peer Group
Oncosil Medical Ticker
Oncosil Medical FIGI
All fundamentals and in-depth analysis of Oncosil Medical
Our stock analysis for Oncosil Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncosil Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.